In 2005 an external evaluation of the Medicines for Malaria Venture was commissioned by the Donor Coordination Group on product development public-private partnerships (PD-PPPs), which includes the World Bank. This Global Program Review assesses the quality and independence of that evaluation, provides a second opinion, assesses the World Bank's performance as a partner of MMV, and draws lessons for the future of MMV and the World Bank's relationship with it and other PD-PPPs. It is concluded that MMV is efficient, effective and successful at drug research and development, although it is too early to say how successful it will be at the very different task of improving access to and delivery of the drugs.
Report no. June 26, 2007, Sector, Thematic, and Global Evaluation Unit (World Bank); xx + 72 pp.
Global program review: Medicines for Malaria Venture.